Citation :
DBV Technologies down 61% after FDA cancels APAC meeting for Viaskin Peanut BLA DBV Technologies was halted after the close of the market, news pending. Then the company announced that the FDA informed it that during its ongoing review of the Biologics License Application, or BLA, for investigational Viaskin Peanut, it identified questions regarding efficacy, and canceled the May 15 Allergenic Products Advisory Committee, or APAC, meeting to discuss the BLA. DBV Technologies' stock resumed trading in the after hours, and is down 61% to $2.05 per share
|